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A B S T R A C T
This study compared the clinical, laboratory and
radiological features of infections caused by hu-
man metapneumovirus (hMPV) with other res-
piratory viruses. Nasopharyngeal aspirates and
throat swabs were obtained from children during
a 9-week period. hMPV was the virus isolated
most frequently, followed by adenovirus, influ-
enza virus A, respiratory syncytial virus and
influenza virus B. hMPV-infected children were
younger, and were more likely to be female, to
present with feeding difficulties, a rash, tachycar-
dia and a longer duration of fever, and to cough
less frequently. Increasing interstitial infiltrates
and hyperinflation were the most common radio-
logical findings. None of the children required
mechanical ventilation.
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Acute respiratory tract infection (RTI) is the most
common disease among individuals of all ages
worldwide [1]. RTIs are a major cause of child-
hood morbidity and mortality in the developing
world [2], but despite sensitive diagnostic meth-
ods, an aetiological agent can be identified in only
35% of children with acute RTIs [3]. Human
metapneumovirus (hMPV) was first isolated in
The Netherlands in 2001 from nasopharyngeal
aspirates obtained from young children suffering
mild-to-severe RTIs [4]. hMPV is related closely to
respiratory syncytial virus, but can be clearly
differentiated by its cytopathic effect on tertiary
monkey kidney cells, an absence of haemag-
glutinating activity, and its morphology on elec-
tron-microscopy. hMPV has been detected in
respiratory specimens from patients of all ages
in Canada, Australia, the UK, Finland and Hong
Kong [5–11].
During the spring of 2004, clusters of RTIs in
children were larger and more numerous than
seen previously at the National Cheng Kung
Hospital, located in southern Taiwan, indicating a
possible change in viral aetiology. The present
study aimed to determine the most common
aetiological agents associated with this outbreak,
and to compare the clinical symptoms, laboratory
findings and radiological features of hMPV-infec-
ted children with those of children who were
infected with other respiratory viruses (RVs).
The study included 1824 children aged
<16 years who visited the hospital between 1
March and 2 May 2004. Cases of RTI were defined
as children who presented with signs and symp-
toms of acute RTI, and who had a nasopharyngeal
aspirate or a throat swab collected at admission.
Peripheral blood was collected as warranted by
the clinical circumstances. Nasopharyngeal aspi-
rates or throat swabs were inoculated into cell
cultures, including MDCK, Vero, A549 and rhab-
domyosarcoma cells, and were then incubated for
14 days. A positive cytopathic effect was con-
firmed by immunofluorescent staining with
monoclonal antibodies or, in the case of hMPV,
by RT-PCR using a OneStep RT-PCR kit (Qiagen,
Hilden, Germany) with antisense primer MPVF1r
(5¢-GTCTTCCTGTGCTAACTTTG) and sense pri-
mer MPVF1f (5¢-CTTTGGACTTAATGACAGA-
TG) to detect the fusion protein gene [5,12].
Rapid viral antigen detection by immunofluores-
cence was performed using commercial assays
(Chemicon International, Temecula, CA, USA).
RVs were identified in 78 (23.0%) of 339
children with RTI. hMPV was the most frequent
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virus isolated (n = 37, 47.4%), followed by
adenovirus (n = 18, 23.1%), influenza virus A
(n = 12, 15.4%), respiratory syncytial virus
(n = 9, 11.5%) and influenza virus B (n = 2,
2.6%). The weekly prevalence of patients infect-
ed with hMPV, adenovirus, influenza and res-
piratory syncytial virus is shown in Fig. 1.
The demographical and clinical findings for the
patients are summarised in Table 1. Children
with hMPV were significantly younger than those
with other RV infections. Most children with
hMPV were aged 6–18 months, and all were aged
<5 years. Children with hMPV were significantly
more likely to be female, and to present with
feeding difficulties, rash and tachycardia, but
were noted to cough less frequently. Children
with hMPV had fever lasting, on average, for
1 day longer than children with other RVs.
Thirteen children had diarrhoea, and seven
children with hMPV had a non-pruritic, maculo-
papular and transient rash on their trunk and
back. Both groups frequently had underlying
illness, and c. 60% required hospitalisation.
The laboratory and radiological findings are
summarised in Table 2. Other bacteria or viruses
were detected in clinical specimens from six
hMPV-infected children and four children with
other RV infections. The overall rate of dual
infection was 12.8%. A chest X-ray was obtained
for 71.8% of the children. The most common
findings in both groups were increasing intersti-
tial infiltrates and hyperinflation. Nine children
with hMPV and six with other RVs required
additional oxygen. Eighteen hMPV-infected chil-
dren were treated with antibiotics for a median of
5 days (range 1–14 days). The median hospitali-
sation period for all hMPV-infected children was
4 days (range 2–11 days). No hMPV-infected
patient required mechanical ventilation or admit-
tance to the intensive care unit.
Overall, the key findings of the current study
included the following observations. First,
hMPV is clearly a respiratory pathogen with
an apparently unique epidemic pattern. Second,
hMPV contributes substantially to acute RTI
among children. Third, the respiratory symp-
toms and signs associated with hMPV are
similar to those of other RVs. Fourth, the
duration of fever, presence of a skin rash, and
presentation with feeding difficulties, tachycar-
dia and minimal cough are helpful diagnostic
signs and symptoms. Fifth, a decreasing abso-
lute lymphocyte count was not observed in
hMPV-infected patients, but was encountered in
other severe virus infections. Finally, the results
suggest a different seasonal pattern of hMPV
infection among children when compared with
other RVs, although this needs to be confirmed
by a longer period of observation.
Cases of severe hMPV infection among adults
[10] and of re-infection among immunocompro-
mised individuals [13] suggest that, despite uni-
versal infection in childhood, new infections can
occur throughout life because of a protective
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Fig. 1. Weekly prevalence of human metapneumovirus
(hMPV), adenovirus, influenza virus A (Influ A), influenza
virus B (Influ B) and respiratory syncytial virus (RSV)
infections between 1 March and 2 May 2004. Numbers in
parentheses are the number of cases examined per week.
Table 1. Demographical and clinical data for patients
infected with human metapneumovirus (hMPV) and other
respiratory viruses (RVs) during a Taiwanese outbreak
Characteristic hMPV (n = 37) Other RVs (n = 41) p
Demographical data
Mean age (months) 22.9 ± 15.6 50.1 ± 46.9 0.005
6–18 months, no. (%) 14 (37.8) 5 (12.2) 0.008
>60 months, no. (%) 0 10 (24.4) 0.001
Male gender, no. (%) 13 (35.1) 26 (63.4) 0.013
Underlying illness, no. (%) 11 (29.7) 12 (29.3) 0.964
Hospitalisation, no. (%) 25 (67.6) 24 (58.5) 0.41
Clinical diagnosis
Acute gastroenterocolitis, no. (%) 6 (16.2) 5 (12.2) 0.61
Bronchiolitis ⁄ bronchitis, no. (%) 6 (16.2) 6 (14.6) 0.847
Bronchopneumonia, no. (%) 9 (24.3) 9 (22.0) 0.804
Oral ulcer, no. (%) 2 (5.4) 2 (4.8) 0.916
Pharyngitis, no. (%) 9 (24.3) 17 (41.5) 0.109
Viral exanthems, no. (%) 5 (13.5) 0 0.015
Clinical features
Fever
Maximum (C) 38.8 ± 0.6 39.0 ± 0.7 0.315
Duration (days) 4.3 ± 2.0 3.1 ± 2.4 0.046
Cough, no. (%) 26 (70.3) 39 (95.1) 0.003
Rhinorrhoea, no. (%) 17 (45.9) 25 (61.0) 0.184
Hypoxaemia, no. (%) 5 (24.3) 1 (2.4) 0.067
Feeding difficulties, no. (%) 24 (64.9) 16 (39.0) 0.023
Nausea ⁄vomiting, no. (%) 7 (18.9) 14 (34.1) 0.13
Diarrhoea, no. (%) 13 (35.1) 11 (26.8) 0.071
Rash, no. (%) 7 (18.9) 1 (2.4) 0.017
Sore throat ⁄ injected throat, no. (%) 22 (59.5) 32 (78.0) 0.076
Tachycardia, no. (%) 21 (56.8) 5 (12.2) 0.001
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immune response that is incomplete and ⁄ or the
acquisition of new genotypes. Eleven hMPV-
infected and 12 non-hMPV-infected patients in
the current series had an underlying illness. There
were no differences in outcome between patients
with or without associated underlying disease.
This contrasts with other reports of severe out-
comes in individuals with underlying disease, as
well as in infants and the elderly [12].
Rapid, sensitive and reproducible diagnostic
tests for hMPV may reduce virus transmission
among children in hospital wards, particularly
when combined with isolation or alternative
measures used currently to limit the spread of
other RVs. The RT-PCR procedure, based on
amplification of a conserved sequence in the
fusion gene, proved to be more sensitive than
virus isolation. The use of PCR is particularly
advantageous, as hMPV is fastidious and difficult
to grow in most cell lines. Inclusion of hMPV in
real-time diagnostic testing of patients with RTI
may reduce the unnecessary use of antibiotics.
In conclusion, this is the first report of hMPV,
as well as the largest single-season case series of
hMPV to date, from Taiwan. hMPV infection
should be considered as an emerging disease and
as a common cause of acute RTI in childhood. The
outcome is generally favourable with supportive
treatment.
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Laboratory data
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Increasing interstitial infiltrate, no. (%) 17 (58.6) 17 (63.0) 0.74
Microbiological studies
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Therapy
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A B S T R A C T
A prospective cohort study was performed to
collect baseline data concerning surgical site
infections (SSIs) and antimicrobial prophylaxis
(AMP) in a remote sub-Saharan district hospital.
The SSI rate of 22% was high. Most (88%) of the
patients received prophylaxis after incision, and
only 5% within the 30-min period before incision.
Of all pathogens isolated from SSIs, 60% were
resistant to the agent administered. The antibiot-
ics given most frequently were chloramphenicol
(60%), aminopenicillins (23%) and benzylpenicil-
lin (15%). Staphylococcus aureus (36%), Escherichia
coli (5%) and enterococci (4%) were the patho-
gens isolated most commonly from SSIs.
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Surgical site infections (SSIs) are the second most
common cause of nosocomial infection, resulting
in considerable morbidity and mortality. Antimi-
crobial prophylaxis (AMP) reduces the rate of
SSI in non-clean surgery. In accordance with
guidelines, perioperative AMP is administered
routinely in industrialised countries to all patients
who qualify [1,2]. Data concerning comparative
perioperative AMP in non-industrialised and
industrialised nations are scarce [3–6]. The present
study provides, for the first time, data concerning
AMP in a rural sub-Saharan district hospital.
The study was conducted in the 82-bed depart-
ment of general surgery, which includes gynae-
cology and obstetrics, of the St Francis Designated
District Hospital in Ifakara, southern Tanzania.
The St Francis Designated District Hospital is a
371-bed hospital that serves a region with a
population of >550 000. A mean of 155 surgical
procedures are performed every month in the two
main operating rooms. Between November 2003
and March 2004, all consecutive adult patients
admitted for surgery were enrolled in the study.
Data concerning patient characteristics, laborat-
ory results, type of surgical intervention and
administration of AMP were recorded continu-
ously by study nurses (24 h, 7 days a week). No
written guidelines concerning the use of AMP
were available in the hospital; antibiotics and
dosages were chosen by the surgeon.
In cases of suspected SSI, the site of infection
was documented with a digital camera and swab
samples were taken. During the study, data were
reviewed and checked prospectively by a senior
infectious diseases specialist. Material from swabs
was analysed by Gram’s stain and plated on
CHROMagar Orientation and CHROMagar Sta-
phylococcus aureus (Becton Dickinson, Heidelberg,
Germany) in the local laboratory. Colonies isola-
ted were subcultured and transported to the
Microbiology Laboratory, University Hospital Ba-
sel, Switzerland, for further analysis using stand-
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